Inactief instrument

Andere talen iQX Limited

Aandelen

IQX : Continued Suspension - Non-payment of Annual Listing Fee 2022-2023	15-08-22
IQX : Execution Of Deed Of Company Arrangement	05-08-22
IQX : Outcome Of Creditors' Meeting	01-08-22
IQX : Continued Suspension - Failure to lodge Half Yearly Financial Statements- 31 December 2021	17-03-22
IQX : The phone number for the Voluntary Administrator was incorrect and nothing else has changed.	15-03-22
IQX : seeks Voluntary Administration today to restructure	10-03-22
IQX Limited Worldwide License for Harvard Uni's eRapid Technology	07-03-22
IQX : Antisoma Therapeutics secures worldwide license for Harvard University’s eRapid technology for at-home diagnostic testing	07-03-22
IQX : Director's declaration and undertaking on behalf of Vincenzo Milazzo	15-12-21
IQX : Appointment/Resignation of Company Secretary	13-12-21
IQX : FDA Breakthrough Devices Designation application to fast track rapid saliva glucose testing	13-12-21
IQX Limited (NSX:IQX) FDA Breakthrough Devices Designation	13-12-21
IQX : Initial Director's Interest-Vincenzo Milazzo	25-11-21
IQX : Final Director's Interest-John Stratilas	25-11-21
IQX : Appointment of Director Vincenzo Milazzo and Resignation of Director John Stratilas	25-11-21
IQX : Results of AGM FY2021	19-11-21
IQX Chairman's Address to Shareholders AGM: 19 November 2021	18-11-21
IQX Limited Wyss Validation Study SARS-CoV-2	10-11-21
IQX Limited OncoTEX Gold Compound Licensing	04-11-21
IQX : Filed a Pre-Submission package with the United States (US) Food and Drug Administration (FDA).	19-10-21

Geen resultaten voor deze zoekopdracht